1-5 of 5
Frank Haluska, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

Daryl Sonnichsen, David Dorer, Jorge E. Cortes, Moshe Talpaz, MD, Michael W. Deininger, MD, PhD, Neil Shah, MD, PhD, Hagop M. Kantarjian, Dale Bixby, MD PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Jeffrey Litwin, MD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4441.
https://doi.org/10.1182/blood.V118.21.4441.4441
Published: 2011
Journal Articles

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp D. Le Coutre, Priv. Doz. Dr., Charles Chuah, MBChB, FRCPE, MD, Franck E Nicolini, MD, Ron Paquette, MD, PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, H. Jean Khoury, MD, FACP, Delphine Rea, MD, PhD, Moshe Talpaz, MD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, Michele Baccarani, MD, Martin C Mueller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Christopher D. Turner, MD, FAAP, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop M. Kantarjian, The PACE Study Group
Journal: Blood
Blood (2011) 118 (21): 109.
https://doi.org/10.1182/blood.V118.21.109.109
Published: 2011
Journal Articles

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Jorge E. Cortes, Hagop M. Kantarjian, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, Simin Hu, PhD, Tim Clackson, PhD, Victor M. Rivera, PhD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD, Brian J. Druker, Michael W. Deininger, Moshe Talpaz, MD
Journal: Blood
Blood (2011) 118 (21): 602.
https://doi.org/10.1182/blood.V118.21.602.602
Published: 2011
Journal Articles

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Jorge Cortes, MD, Moshe Talpaz, MD, Dale Bixby, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W. Flinn, MD, PhD, Michael Mauro, MD, Thomas O'Hare, PhD, Simin Hu, PhD, Rebecca Kan, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2010) 116 (21): 210.
https://doi.org/10.1182/blood.V116.21.210.210
Published: 2010
Journal Articles

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Jorge Cortes, MD, Moshe Talpaz, MD, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W Flinn, MD, Michael J. Mauro, MD, Thomas O'Hare, PhD, Natalie Spinos, Simin Hu, PhD, Lori Berk, Narayana Narasimhan, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 643.
https://doi.org/10.1182/blood.V114.22.643.643
Published: 2009